Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

Based in Mass­a­chu­setts, Lark­spur Bio­sciences, a biotech fo­cused on de­vel­op­ing new im­muno-on­col­o­gy treat­ments, is now armed with $35.5 mil­lion in com­bined seed/Se­ries A back­ing.

The round, led by the Po­laris In­no­va­tion Fund, 3E Bioven­tures Cap­i­tal and Take­da’s VC arm, will help fund de­vel­op­ment of new ther­a­pies for col­orec­tal can­cer.

Lark­spur CEO Cather­ine Sabatos-Pey­ton, a for­mer ex­ec di­rec­tor at No­var­tis In­sti­tutes for Bio­Med­ical Re­search, has been run­ning the com­pa­ny in stealth mode since No­vem­ber. She told End­points News that she got in­volved with Lark­spur in 2021, orig­i­nal­ly as the chief sci­ence of­fi­cer. Sabatos-Pey­ton did her PhD un­der the tute­lage of Vi­jay Kuchroo, one of the co-founders of Lark­spur, while at Har­vard Uni­ver­si­ty study­ing au­toim­mu­ni­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER